CUMBERLAND PHARMACEUTICALS (CPIX) Fundamental Analysis & Valuation

NASDAQ:CPIX • US2307701092

3.49 USD
-0.03 (-0.85%)
Last: Mar 6, 2026, 01:41 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CPIX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, CPIX scores 3 out of 10 in our fundamental rating. CPIX was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of CPIX is average, but there are quite some concerns on its profitability. CPIX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. CPIX Profitability Analysis

1.1 Basic Checks

  • CPIX had positive earnings in the past year.
  • CPIX had a positive operating cash flow in the past year.
  • CPIX had negative earnings in each of the past 5 years.
  • In multiple years CPIX reported negative operating cash flow during the last 5 years.
CPIX Yearly Net Income VS EBIT VS OCF VS FCFCPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • CPIX's Return On Assets of -5.05% is fine compared to the rest of the industry. CPIX outperforms 74.09% of its industry peers.
  • Looking at the Return On Equity, with a value of -12.74%, CPIX is in the better half of the industry, outperforming 72.54% of the companies in the same industry.
Industry RankSector Rank
ROA -5.05%
ROE -12.74%
ROIC N/A
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
CPIX Yearly ROA, ROE, ROICCPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

  • CPIX has a Gross Margin of 84.49%. This is amongst the best in the industry. CPIX outperforms 87.56% of its industry peers.
  • CPIX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CPIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
CPIX Yearly Profit, Operating, Gross MarginsCPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CPIX Health Analysis

2.1 Basic Checks

  • CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPIX Yearly Shares OutstandingCPIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CPIX Yearly Total Debt VS Total AssetsCPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 0.82, we must say that CPIX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.82, CPIX is in line with its industry, outperforming 55.44% of the companies in the same industry.
  • CPIX has a debt to FCF ratio of 0.79. This is a very positive value and a sign of high solvency as it would only need 0.79 years to pay back of all of its debts.
  • CPIX has a better Debt to FCF ratio (0.79) than 96.37% of its industry peers.
  • CPIX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
  • CPIX has a Debt to Equity ratio (0.20) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.79
Altman-Z 0.82
ROIC/WACCN/A
WACC8.85%
CPIX Yearly LT Debt VS Equity VS FCFCPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that CPIX should not have too much problems paying its short term obligations.
  • CPIX has a worse Current ratio (1.23) than 77.72% of its industry peers.
  • A Quick Ratio of 1.11 indicates that CPIX should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.11, CPIX is not doing good in the industry: 74.61% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.11
CPIX Yearly Current Assets VS Current LiabilitesCPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CPIX Growth Analysis

3.1 Past

  • CPIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 237.50%, which is quite impressive.
  • Measured over the past years, CPIX shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.73% on average per year.
EPS 1Y (TTM)237.5%
EPS 3YN/A
EPS 5Y-1.73%
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%31.03%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPIX Yearly Revenue VS EstimatesCPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CPIX Yearly EPS VS EstimatesCPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2023 2024 2025 0 0.2 -0.2

More info and screens

Find the best growth stocksShow best growing peers

3

4. CPIX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 31.73 indicates a quite expensive valuation of CPIX.
  • Based on the Price/Earnings ratio, CPIX is valued a bit cheaper than the industry average as 78.76% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.69. CPIX is around the same levels.
Industry RankSector Rank
PE 31.73
Fwd PE N/A
CPIX Price Earnings VS Forward Price EarningsCPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CPIX is valued a bit cheaper than 76.17% of the companies in the same industry.
  • 93.78% of the companies in the same industry are more expensive than CPIX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.83
EV/EBITDA 88.71
CPIX Per share dataCPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPIX Dividend Analysis

5.1 Amount

  • No dividends for CPIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPIX Fundamentals: All Metrics, Ratios and Statistics

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (3/6/2026, 1:41:02 PM)

3.49

-0.03 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners22.93%
Inst Owner Change-14.62%
Ins Owners3.53%
Ins Owner Change0.02%
Market Cap52.21M
Revenue(TTM)N/A
Net Income(TTM)-3.33M
Analysts43.33
Price TargetN/A
Short Float %2.21%
Short Ratio0.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 31.73
Fwd PE N/A
P/S 1.26
P/FCF 7.83
P/OCF 7.64
P/B 2
P/tB 5.12
EV/EBITDA 88.71
EPS(TTM)0.11
EY3.15%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.45
FCFY12.77%
OCF(TTM)0.46
OCFY13.09%
SpS2.76
BVpS1.75
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.08
Profitability
Industry RankSector Rank
ROA -5.05%
ROE -12.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.49%
FCFM 16.16%
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.79
Debt/EBITDA 10.89
Cap/Depr 4.41%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion 1419.63%
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.11
Altman-Z 0.82
F-Score8
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)17.26%
Cap/Depr(5y)20.78%
Cap/Sales(3y)2.19%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)237.5%
EPS 3YN/A
EPS 5Y-1.73%
EPS Q2Q%50%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%31.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.37%
OCF growth 3YN/A
OCF growth 5YN/A

CUMBERLAND PHARMACEUTICALS / CPIX FAQ

Can you provide the ChartMill fundamental rating for CUMBERLAND PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 3 / 10 to CPIX.


Can you provide the valuation status for CUMBERLAND PHARMACEUTICALS?

ChartMill assigns a valuation rating of 3 / 10 to CUMBERLAND PHARMACEUTICALS (CPIX). This can be considered as Overvalued.


How profitable is CUMBERLAND PHARMACEUTICALS (CPIX) stock?

CUMBERLAND PHARMACEUTICALS (CPIX) has a profitability rating of 3 / 10.


What is the financial health of CUMBERLAND PHARMACEUTICALS (CPIX) stock?

The financial health rating of CUMBERLAND PHARMACEUTICALS (CPIX) is 4 / 10.